---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Drug interactions questions"
description: "Drug interactions questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What are the drug interactions with Trelegy? Can Trelegy be taken with ketoconazole, ritonavir, or other strong CYP3A4 inhibitors? Have drug interaction studies been done with Trelegy? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta/drug-interactions"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Drug interactions questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)  
Indication pages: [Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)

## Drug interactions

<a id="trelegy-drug-interactions"></a>

### What are the drug interactions with Trelegy?

> “TRELEGY should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval, or within 2 weeks of discontinuation of such agents, because they may potentiate the effect of vilanterol on the cardiovascular system.
> Use beta-blockers with caution, as they not only block the pulmonary effect of beta-agonists, such as vilanterol, but may produce severe bronchospasm in patients with COPD or asthma.
> Use with caution in patients taking non–potassium-sparing diuretics, as ECG changes and/or hypokalemia associated with these diuretics may worsen with concomitant beta-agonists.
> Avoid coadministration of TRELEGY with other anticholinergic-containing drugs, as this may lead to an increase in anticholinergic adverse effects.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=TRELEGY%20should%20be%20administered%20with,increase%20in%20anticholinergic%20adverse%20effects.)

<a id="trelegy-cyp3a4-inhibitors"></a>

### Can Trelegy be taken with ketoconazole, ritonavir, or other strong CYP3A4 inhibitors?

> “Caution should be exercised when considering the coadministration of TRELEGY with ketoconazole and other known strong CYP3A4 inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased systemic corticosteroid and cardiovascular adverse effects may occur.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Caution%20should%20be%20exercised%20when,cardiovascular%20adverse%20effects%20may%20occur.)

> “Inhibitors of Cytochrome P450 3A4: The exposure (AUC) of fluticasone furoate and vilanterol 
> were 36% and 65% higher, respectively, when coadministered with ketoconazole 400 mg 
> compared with placebo (Figure 3). The increase in fluticasone furoate exposure was associated 
> with a 27% reduction in weighted mean serum cortisol (0 to 24 hours). The increase in vilanterol 
> exposure was not associated with an increase in beta-agonist–related systemic effects on heart 
> rate or blood potassium.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 31, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=31)

<a id="trelegy-drug-interaction-studies"></a>

### Have drug interaction studies been done with Trelegy?

> “No drug-drug interaction studies have been conducted with TRELEGY ELLIPTA. The 
> information below is from drug-drug interaction studies conducted with umeclidinium, 
> fluticasone furoate/vilanterol, or umeclidinium/vilanterol. The potential for fluticasone furoate, 
> umeclidinium, and vilanterol to inhibit or induce metabolic enzymes and transporter systems is 
> negligible at low inhalation doses.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 31, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=31)

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): All indications](https://www.evicenter.com/medical-information/trelegy-ellipta)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trelegy-ellipta/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/trelegy-ellipta/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trelegy-ellipta/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/trelegy-ellipta/access-and-coverage)
